16.12.2012 Views

24/06/2005 - Controller General of Patents, Designs, and Trade Marks

24/06/2005 - Controller General of Patents, Designs, and Trade Marks

24/06/2005 - Controller General of Patents, Designs, and Trade Marks

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

(12) PATENT APPLICATION PUBLICATION<br />

(19) INDIA (21)<br />

(22) Date <strong>of</strong> filing <strong>of</strong> Application: 20/01/2004 (43)<br />

Application No: 00051/MUMNP/2004 A<br />

Publication Date: <strong>24</strong>/<strong>06</strong>/<strong>2005</strong><br />

(54) Title <strong>of</strong> the invention: CONTROLLED RELEASE FORMULATION OF LAMOTRIGINE<br />

(51) International Classification : C 07 D 3/00 (71)<br />

(31) Priority Document No. : 60/386,795<br />

(32) Priority Date : 07/<strong>06</strong>/2002<br />

(33) Name <strong>of</strong> priority country : USA<br />

(86) International Application<br />

No.<br />

: PCT/IN03/00213<br />

Filing Date : <strong>06</strong>/<strong>06</strong>/2003<br />

(87) International Publication<br />

No.<br />

: WO 03/104192 A2<br />

(61) Patent <strong>of</strong> addition to<br />

Application No.<br />

: NIL<br />

Filed on : N.A.<br />

(62)<br />

(57) Abstract:<br />

Divisional to Application<br />

No.<br />

: NIL<br />

Filed on : N.A.<br />

(72)<br />

Name <strong>of</strong> the Applicant:<br />

TORRENT PHARMACEUTICALS<br />

LIMITED<br />

Address <strong>of</strong> the Applicant:<br />

TORRENT HOUSE,<br />

OFF ASHRAM ROAD,<br />

DINESH HALL,<br />

AHMEDABAD – 380 009,<br />

GUJARAT, INDIA.<br />

Name <strong>of</strong> the Inventors:<br />

1. NADKARNI SUNIL SADANAND<br />

Filed U/S 5(2) before the<br />

<strong>Patents</strong> (Amendment)<br />

Ordinance, 2004: NO<br />

Rapidly disintegrating multiparticulate controlled release formulations <strong>of</strong> lamotrigine having an improved<br />

pharmacokinetic pr<strong>of</strong>ile <strong>and</strong> improved patient compliance, <strong>and</strong> process <strong>of</strong> preparing the formulations. It provides<br />

better control <strong>of</strong> blood plasma levels than conventional tablet formulations that is administered once or more<br />

times a day.<br />

(FIG.: NIL)<br />

Total Pages: 26.<br />

The Patent Office Journal <strong>24</strong>.<strong>06</strong>.<strong>2005</strong> 17896

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!